PMID- 24841278
OWN - NLM
STAT- MEDLINE
DCOM- 20150414
LR  - 20211203
IS  - 1098-1101 (Electronic)
IS  - 0733-2459 (Linking)
VI  - 29
IP  - 4
DP  - 2014 Aug
TI  - Peripheral stem cell collection: from leukocyte growth factor to removal of 
      catheter.
PG  - 199-205
LID - 10.1002/jca.21329 [doi]
AB  - A wide variety of hematologic malignancies, autoimmune diseases, inborn errors of 
      metabolism, and bone marrow failure syndromes maybe put into a remission or 
      potentially cured by hematopoietic stem cell transplantation (HSCT). Depending on 
      the underlying disorder, stem cells may be collected from the future transplant 
      recipient themselves, an human leukocyte antigen (HLA) identical donor, a 
      mismatched related or unrelated donor, or banked umbilical cord blood. Peripheral 
      blood leukapheresis to collect stem cells from autologous or allogeneic donors is 
      safe and well-tolerated. In most cases, the apheresis procedure is performed in 
      an outpatient setting over 4-6 h a day for up to 4 days to achieve the stem cell 
      dose needed for HSCT. Current research in stem cell mobilization and collection 
      is focused on optimizing the numbers of stem cells collected by improving 
      mobilization regimens, and increasing the efficiency of the apheresis collection 
      to reduce the number of apheresis procedures needed to meet the stem cell dose 
      requirement for HSCT.
CI  - (c) 2014 Wiley Periodicals, Inc.
FAU - Kindwall-Keller, Tamila
AU  - Kindwall-Keller T
AD  - Division of Hematology/Oncology, University of Virginia, Stem Cell Transplant 
      Program, Emily Couric Clinical Cancer Center, Charlottesville, Virginia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140520
PL  - United States
TA  - J Clin Apher
JT  - Journal of clinical apheresis
JID - 8216305
RN  - 0 (Benzylamines)
RN  - 0 (Cyclams)
RN  - 0 (Heterocyclic Compounds)
RN  - S915P5499N (plerixafor)
SB  - IM
MH  - Allografts
MH  - Benzylamines
MH  - Blood Cell Count
MH  - Blood Component Removal/instrumentation/*methods
MH  - Blood Donors
MH  - Bone Marrow/drug effects
MH  - Cyclams
MH  - Drug Administration Schedule
MH  - Gastrointestinal Diseases/chemically induced
MH  - Hematologic Neoplasms/therapy
MH  - Hematopoietic Stem Cell Mobilization/methods
MH  - Heterocyclic Compounds/pharmacology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Peripheral Blood Stem Cell Transplantation/adverse effects/*methods
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - G-CSF
OT  - apheresis collection efficiency
OT  - plerixafor
OT  - stem cell mobilization
EDAT- 2014/05/21 06:00
MHDA- 2015/04/15 06:00
CRDT- 2014/05/21 06:00
PHST- 2014/03/23 00:00 [received]
PHST- 2014/05/01 00:00 [accepted]
PHST- 2014/05/21 06:00 [entrez]
PHST- 2014/05/21 06:00 [pubmed]
PHST- 2015/04/15 06:00 [medline]
AID - 10.1002/jca.21329 [doi]
PST - ppublish
SO  - J Clin Apher. 2014 Aug;29(4):199-205. doi: 10.1002/jca.21329. Epub 2014 May 20.